E047 I felt like I’d been given a new lease of life: Exploring the information needs and experiences of people with rheumatoid arthritis receiving bridging glucocorticoids when starting methotrexate

Abstract Background/Aims Many people diagnosed with rheumatoid arthritis (RA) receive intramuscular (IM) or oral bridging glucocorticoids whilst methotrexate (MTX) takes effect. Little is known about the information needs and experiences of RA receiving when starting MTX. Methods Seventy-six adults referred for MTX counselling attending two rheumatology units in West Midlands were invited to take part qualitative semi-structured interviews (either by phone video). Research partners helped develop interview topic guides. Interviews digitally recorded, transcribed analysed using reflexive thematic analysis. Results Nineteen participants, (11 male, 8 Female, White British, age 45-76 years, disease duration 6 weeks - 35 years) took telephone (n17) video (n2) (duration 34-82 minutes). Most received IM (n14) before Three themes identified; trusting rheumatologist; provision information; benefits glucocorticoids. Trusting rheumatologist: Several accepted rheumatologist’s decision have a glucocorticoid injection following diagnosis. Some did not understand purpose injection, wanted rationale including how long benefit would last whether could be repeated. Provision information: informed nurse that should help their condition. The majority any written information. This left wondering injections Whereas most treated recalled issued steroid card. Few reported concerns side-effects from seek on internet. One declined reporting enough make an decision. Benefit glucocorticoids: significant glucocorticoids, experiencing relief pain, swelling stiffness joints. found it easier manage personal care noted improved sleep reduced levels fatigue. allowed many resume roles. symptoms gave them hope treatment better quality life RA. Conclusion Treatment often provides rapid waiting established. little no know likely they side-effects. Tailored treatment, plan considered. Disclosure S.J. Logan: None. S. Hider: J. Green: Ryan: